A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer"

Lung Cancer. 2020 Oct:148:181. doi: 10.1016/j.lungcan.2020.07.031. Epub 2020 Aug 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Exons / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors